VAV1 represses E-cadherin expression through the transactivation of Snail and Slug: A potential mechanism for aberrant epithelial to mesenchymal transition in human epithelial ovarian cancer

Translational Research

Volumn 162, Issue 3, 2013, Pages 181-190

  Wakahashi, Senn ^b   Sudo, Tamotsu ^a   Oka, Noriko ^b   Ueno, Sayaka ^b   Yamaguchi, Satoshi ^b   Fujiwara, Kiyoshi ^b   Ohbayashi, Chiho ^b   Nishimura, Ryuichiro ^b  

^a HYOGO CANCER CENTER   (Japan)

^b not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PLATINUM DERIVATIVE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VAV1 PROTEIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPRESSOR GENE; RNA INTERFERENCE; STRESS FIBER; TRANSACTIVATION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84882907451     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2013.06.005     Document Type: Article

References (31)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA: a cancer journal for clinicians 60 2010 277 300
2. R.D. Hightower, H.N. Nguyen, H.E. Averette, W. Hoskins, T. Harrison, and A. Steren National survey of ovarian carcinoma: IV. Patterns of care and related survival for older patients Cancer 73 1994 377 383
3. H.E. Averette, M.F. Janicek, and H.R. Menck The National Cancer Data Base report on ovarian cancer: American College of Surgeons Commission on Cancer and the American Cancer Society Cancer 76 1995 1096 1103
4. A. Bamias, A. Karadimou, and N. Soupos Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience Gynecol Oncol 123 2011 37 42
5. R.C. Young, L.A. Walton, and S.S. Ellenberg Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials N Engl J Med 322 1990 1021 1027
6. X.R. Bustelo Regulatory and signaling properties of the Vav family Mol Cell Biol 20 2000 1461 1477
7. G. Lazer, and S. Katzav Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? Cell Signalling 23 2011 969 979
8. M. Turner, and D.D. Billadeau VAV proteins as signal integrators for multi-subunit immune-recognition receptors Nat Rev Immunol 2 2002 476 486
9. S. Katzav, D. Martin-Zanca, and M. Barbacid Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells EMBO J 8 1989 2283 2290
10. I. Hornstein, E. Pikarsky, M. Groysman, G. Amir, N. Peylan-Ramu, and S. Katzav The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas J Pathol 199 2003 526 533
11. M.E. Fernandez-Zapico, N.C. Gonzalez-Paz, and E. Weiss Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis Cancer Cell 7 2005 39 49
12. G. Lazer, Y. Idelchuk, V. Schapira, E. Pikarsky, and S. Katzav The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis J Pathol 219 2009 25 34
13. L. Ilan, and S. Katzav Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation PLoS One 7 2012 e29939
14. J. Rapley, V.L. Tybulewicz, and K. Rittinger Crucial structural role for the PH and C1 domains of the Vav1 exchange factor EMBO Rep 9 2008 655 661
15. C. Murga, M. Zohar, H. Teramoto, and J.S. Gutkind Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB Oncogene 21 2002 207 216
16. M.R. Kuhne, G. Ku, and A. Weiss A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation J Biol Chem 275 2000 2185 2190
17. U. Tepass, K. Truong, D. Godt, M. Ikura, and M. Peifer Cadherins in embryonic and neural morphogenesis Nat Rev Mol Cell Biol 1 2000 91 100
18. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
19. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial- mesenchymal transitions in development and disease Cell 139 2009 871 890
20. J. Yang, and R.A. Weinberg Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis Dev Cell 14 2008 818 829
21. A. Vincent-Salomon, and J.P. Thiery Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development Breast Cancer Res 5 2003 101 106
22. A. Cano, M.A. Perez-Moreno, and I. Rodrigo The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression Nat Cell Biol 2 2000 76 83
23. E. Batlle, E. Sancho, and C. Franci The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells Nat Cell Biol 2 2000 84 89
24. K.M. Hajra, D.Y. Chen, and E.R. Fearon The SLUG zinc-finger protein represses E-cadherin in breast cancer Cancer Res 62 2002 1613 1618
25. J. Yang, S.A. Mani, and J.L. Donaher Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
26. M.P. Ponnusamy, I. Lakshmanan, and M. Jain MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells Oncogene 29 2010 5741 5754
27. K. Levanon, C. Crum, and R. Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 2008 5284 5293
28. N. Auersperg, A.S. Wong, K.C. Choi, S.K. Kang, and P.C. Leung Ovarian surface epithelium: biology, endocrinology, and pathology Endocrinol Rev 22 2001 255 288
29. J.C. Cheng, N. Auersperg, and P.C. Leung TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells PLoS One 7 2012 e42436
30. K. Blechschmidt, S. Sassen, B. Schmalfeldt, T. Schuster, H. Hofler, and K.F. Becker The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients Br J Cancer 98 2008 489 495
31. K. Sawada, A.K. Mitra, and A.R. Radjabi Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target Cancer Res 68 2008 2329 2339